Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission

- **BMT330**
  - Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
  - PI: Rezvani
  - Sponsor: Stanford

- **BMT302**
  - Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning & Allogeneic HCT in Acute Leukemia
  - PI: Muffy
  - Sponsor: Stanford

- **FLT3**
  - Mutation

- **BMT322**
  - Phase III FLT3Inhibitor Gilteritinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML
  - PI: Muffy
  - Sponsor: BMT CTN

- **BMT334**
  - Gilteritinib (ASP2215) in FLT3 Mutated Relapsed or Refractory AML or FLT3-Mutated AML in CR w/ MRD
  - PI: Muffy
  - Sponsor: NIH

Advanced Disease

- Matched Related Donor

First (CR1) or Higher Remission

- **BMT336**
  - Phase I/Ii MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells PI: Meyer NIH
  - PI: Meyer
  - NIH

- **BMT326**
  - Phase III Haploidentical HSCT & ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy
  - PI: Johnson
  - Pending

**KEY**

- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Optional Path
- Enrollment on Hold